Form 4: Apellis Pharmaceuticals Acquired by Biogen

Director Paul Fonteyne reports the disposition of all Apellis Pharmaceuticals equity holdings following the company's acquisition by Biogen.

Summary

• Apellis Pharmaceuticals has been acquired by Biogen Inc. via a merger agreement dated March 31, 2026.
• Shareholders received $41.00 per share in cash plus one non-transferable contingent value right (CVR).
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• The merger became effective on May 14, 2026, with Apellis becoming a wholly owned subsidiary of Biogen.
• Director Paul Fonteyne disposed of all direct holdings, including 30,666 shares of common stock and various stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral-to-positive event for shareholders, as the acquisition provides immediate liquidity at a set price, though the outcome of the CVR remains speculative.

Positives

• Shareholders received a definitive cash consideration of $41.00 per share.
• Potential for additional upside through the $4.00 per share CVR component.
• Successful completion of the tender offer and subsequent merger process.

Negatives

• Options with an exercise price of $45.00 or greater were cancelled without any consideration.
• The company ceases to exist as an independent publicly traded entity.

Risks

• The $4.00 per share CVR is contingent upon specific milestones, which may not be achieved.
• The CVR is non-transferable, limiting liquidity for former shareholders.

Future Outlook

Apellis Pharmaceuticals is now a wholly owned subsidiary of Biogen, and its future performance will be integrated into Biogen's consolidated financial reporting.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biopharmaceutical sector, with Biogen expanding its portfolio through the absorption of Apellis's assets and pipeline.

Comparison to Industry Standards

• The use of CVRs in biopharma M&A is a standard mechanism to bridge valuation gaps between buyers and sellers regarding clinical trial outcomes.
• The $41.00 cash offer reflects the premium typically associated with late-stage or commercial-stage biotech acquisitions.

Stakeholder Impact

• Shareholders have been cashed out of their positions.
• Employees and operations are now under the governance of Biogen.

Next Steps

• Integration of Apellis operations into Biogen.
• Monitoring of milestones related to the CVR agreement.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Form 4, Contingent Value Right